Summary
Quest Diagnostics Incorporated (DGX) has announced the pricing of a $500 million public offering of 5.000% senior notes due 2036. This offering, conducted under the company's shelf registration statement, is set to close on May 6, 2026, with net proceeds intended for general corporate purposes. A significant portion of these proceeds may be used to repay existing indebtedness, specifically the $500 million aggregate principal amount of 3.45% Senior Notes maturing on June 1, 2026. This proactive debt management strategy aims to refinance maturing debt with new, longer-term notes. Investors should note the timing of the offering's closing just ahead of the maturity date of the existing notes. The company has also entered into an underwriting agreement with major financial institutions, including Goldman Sachs & Co. LLC, J.P. Morgan Securities LLC, and Mizuho Securities USA LLC, for this transaction.
Key Highlights
- 1Quest Diagnostics priced a $500 million public offering of 5.000% senior notes due 2036.
- 2The company intends to use the net proceeds for general corporate purposes, including potential repayment of indebtedness.
- 3The offering may be used to refinance $500 million of 3.45% Senior Notes maturing on June 1, 2026.
- 4The net proceeds are expected to be received on May 6, 2026, subject to customary closing conditions.
- 5An underwriting agreement has been executed with Goldman Sachs & Co. LLC, J.P. Morgan Securities LLC, and Mizuho Securities USA LLC, among others.